XML 95 R77.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Earnings Per Share [Abstract]    
Net loss $ (45,529) $ (52,666)
Deemed dividend on Series A and Series A-1 Convertible Preferred Stock (7,496)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (53,025) $ (52,666)
Weighted average common shares outstanding, basic 50,515,773 41,756,129
Weighted average common shares outstanding, diluted 50,515,773 41,756,129
Net loss per share - basic [1] $ (1.05) $ (1.26)
Net loss per share - diluted [1] $ (1.05) $ (1.26)
[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.